資源描述：
《乳腺癌內(nèi)科治療新進(jìn)展-胡夕春》由會員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在教育資源-天天文庫。
1、乳腺癌內(nèi)科治療新進(jìn)展胡夕春新藥新方案新理念新藥不良反應(yīng)及處理1.1白蛋白結(jié)合紫杉醇(ABX)ORRPFSABX300mg/m2,Q3W33％ABX100mg/m2,QW×358％ABX150mg/m2,QW×362％多西他賽100mg/m2,Q3W36％1.2EFECT:EvaluationofTreatmentOptionsFollowingAIFailureFulvestrantIMinjectionloading-doseregimen* (n=351)Exemestane25mg/dayorally(n=342)
2、Postmenopausalwomenwith hormonereceptor–positive,progressing/recurringadvancedbreastcancerafternonsteroidalAI(N=693)Progression,death,orwithdrawal*Fulvestrantloading-doseregimencomprised500mgonDay0,250mgonDays14and28,and250mgmonthlythereafter.GradisharW,etal.SABC
3、S2006.Abstract12.EFECT:SimilarTTPinPatientsTreatedWithFulvestrantorExemestaneGradisharW,etal.SABCS2006.Abstract12.00.00.20.40.60.81.034219098412112861ProportionofPatientsProgressionFreeMonthsNo.atRiskFulvestrantExemestane3691215182124273511959650251242000Exemesta
4、neFulvestrantEFECT:PatientResponseandStudyConclusionsMediandurationofresponsetotreatmentwithfulvestrantvsexemestane:13.5vs9.8months,respectivelyFulvestrantaseffectiveandsafeasexemestaneinwomenwithhormonereceptor–positivebreastcancerwhohaveprogressedontreatmentwit
5、hanonsteroidalAIOutcome,%Exemestane(n=342)Fulvestrant (n=351)OddsRatio(95%CI)PValueORR6.77.41.120 (0.578-2.186).7364CBR31.532.21.035 (0.720-1.487).8534GradisharW,etal.SABCS2006.Abstract12.Anthracyclin-pretreatedandtaxaneresistantN:752RANDOMIZáCIóIxabepilone40mg/m
6、2d1靜脈滴注3hCapecitabine1000mg/m2po.BIDx14Capecitabine1250mg/m2po.BIDx141.3Ixabepilone+CapecitabinevsCapecitabineL.T.Vahdatetal.ProcASCO2007.Abstr1006Ixabepilone+CapecitabinevsCapecitabineL.T.Vahdatetal.ProcASCO2007.Abstr1006Ixabepilone+CapecitabinevsCapecitabineL.T
7、.Vahdatetal.ProcASCO2007.Abstr1006新藥新方案新理念新藥不良反應(yīng)及處理2.1LapatiniboraltyrosinekinaseinhibitorofErbB1andErbB2BlockssignalingthroughEGFRandHER2homodimersandheterodimersMayalsopreventsignalingbetweenErbB1/ErbB2andotherErbBfamilymembersPTENLapatinibP13KpAktRasRafpErkShc
8、Grb2So8Phospholipidcell membraneTreatmentEfficacy:LapatinibVsLapatinib+Trastuzumab*ConfirmedCR+PR?CR+PR+SD≥6moClinicalResponseL N=145L+T N=146ResponseRate,%*(9
